He breaks down why access to AI tools doesn't equal adoption, and why the real bottleneck is tying data and technology into actual workflows—with alignment across business, IT, and security and compliance teams. He closes with an optimistic look at how AI, if built on the right foundation, can free teams to focus on the personalization, empathy, and engagement that matter most to patients. Key Takeaways:Learn why traditional commercial playbooks are breaking down as specialty and rare-disease medicines demand more coordinated, technology-enabled patient support. Understand where AI adoption in biopharma really stands today. Hear what separates "good" from "great" in patient experience—and how leading biopharma companies build in the agility to course-correct in real time.